Aegis Downgrades Rosetta Genomics to Hold (ROSG)
Rosetta Genomics (NASDAQ:ROSG) was downgraded by analysts at Aegis from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, TheFlyOnTheWall.com reports. They currently have a $3.50 target price on the stock, down from their previous target price of $10.00. Aegis’ price objective points to a potential upside of 12.90% from the company’s current price.
Rosetta Genomics (NASDAQ:ROSG) traded down 9.68% on Wednesday, hitting $2.80. The stock had a trading volume of 173,586 shares. Rosetta Genomics has a 52 week low of $3.00 and a 52 week high of $7.73. The stock has a 50-day moving average of $3.31 and a 200-day moving average of $3.72. The company’s market cap is $27.5 million.
Rosetta Genomics Ltd. (NASDAQ:ROSG) develops and commercializes diagnostic tests based on microRNAs.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.